BioCentury | Nov 10, 2016
Translation in Brief

Synthetic Staph stopper

...antibiotics using primary sequence from the human microbiome.” Nature Chemical Biology (2016) -- Mark Zipkin Mark Zipkin Micreos B.V. The...
BioCentury | Mar 23, 2016
Company News

Management tracks

...company, effective March 31. COO David Lemus will take over CFO responsibilities. Infectious disease play Micreos B.V....
BioCentury | Feb 22, 2016
Financial News

Micreos completes venture financing

Micreos B.V. , Wageningen, the Netherlands Business: Infectious Date completed: 2016-02-18 Type: Venture financing Raised: EUR12 million ($13.4 million) Investors: Existing investors; and other undisclosed investors WIR Staff Infectious...
BioCentury | Feb 19, 2016
Financial News

Micreos secures EUR 12M

...Antibiotic play Micreos B.V. (Wageningen, the Netherlands) said it raised EUR 12 million ($13.4 million) from undisclosed...
...Wageningen, the Netherlands) said it raised EUR 12 million ($13.4 million) from undisclosed equity investors. Micreos...
...bacteria selectively and are not prone to inducing antibiotic resistance. CEO Mark Offerhaus told BioCentury Micreos...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...based on phage lysins-enzymes that kill bacteria selectively and are not prone to bacterial resistance. Micreos B.V....
...response to the FDA. The company declined to comment on the specifics of the letter. Micreos...
...on open wounds or in surgery because it is not sufficiently pure for systemic exposure. Micreos...
Items per page:
1 - 5 of 5
BioCentury | Nov 10, 2016
Translation in Brief

Synthetic Staph stopper

...antibiotics using primary sequence from the human microbiome.” Nature Chemical Biology (2016) -- Mark Zipkin Mark Zipkin Micreos B.V. The...
BioCentury | Mar 23, 2016
Company News

Management tracks

...company, effective March 31. COO David Lemus will take over CFO responsibilities. Infectious disease play Micreos B.V....
BioCentury | Feb 22, 2016
Financial News

Micreos completes venture financing

Micreos B.V. , Wageningen, the Netherlands Business: Infectious Date completed: 2016-02-18 Type: Venture financing Raised: EUR12 million ($13.4 million) Investors: Existing investors; and other undisclosed investors WIR Staff Infectious...
BioCentury | Feb 19, 2016
Financial News

Micreos secures EUR 12M

...Antibiotic play Micreos B.V. (Wageningen, the Netherlands) said it raised EUR 12 million ($13.4 million) from undisclosed...
...Wageningen, the Netherlands) said it raised EUR 12 million ($13.4 million) from undisclosed equity investors. Micreos...
...bacteria selectively and are not prone to inducing antibiotic resistance. CEO Mark Offerhaus told BioCentury Micreos...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...based on phage lysins-enzymes that kill bacteria selectively and are not prone to bacterial resistance. Micreos B.V....
...response to the FDA. The company declined to comment on the specifics of the letter. Micreos...
...on open wounds or in surgery because it is not sufficiently pure for systemic exposure. Micreos...
Items per page:
1 - 5 of 5